Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients

Assessing the efficacy of Naltrexone as augmentation to SSRI in patients with OCD

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obsessive Compulsive Disorder Anxiety Disorders Mental Disorders Obsessive-Compulsive Disorder

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chaim Sheba Medical Center

Ramat Gan, 52621, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of OCD
Treatment with SSRI for at least 10 weeks with no response

Exclusion criteria

Suffering from any medical condition
treatment with opiates
chronic use of drugs
Hepatitis or other liver related diseases
Incapability to sign an informed consent

Treatment and study plan

Naltrexone

Drug

Sponsors and collaborators

Lead sponsor

Sheba Medical Center

Other Gov

Registry information

Important dates

Study start: 2002
Primary completion: 2004
Study completion: 2004
First posted: Oct 7, 2005
Registry last updated: Jan 30, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed